Figure 7 | Scientific Reports

Figure 7

From: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease

Figure 7

Exendin-4 mediated protection in TH neurons is associated with the plasma Exendin-4 level. (a) A significant positive correlation was found between normalized striatal TH-IR (i.e., lesioned/non-lesioned side) and plasma Exendin-4 levels (p = 0.002, R = 0.663). (b) Plasma Exendin-4 levels were significantly correlated with TH-IR in the substantia nigra on the lesioned side (p < 0.001, R = 0.842).

Back to article page